NCT01658969: Laboratory Treated T Cells After Chemotherapy in Treating Patients With HER2-Negative Stage II-III Breast Cancer That Can Be Removed By Surgery |
|
|
| Recruiting | 2 | 48 | US | Doxorubicin, ADM, ADR, Adria, Adriamycin PFS, Adriamycin RDF, Rubex, Cyclophosphamide, Cytoxan, CPM, CTX, Endoxan, Endoxana, Paclitaxel, Anzatax, Asotax, TAX, Taxol, Onxal™, Docetaxel, RP 56976, Taxotere, TXT, HER2Bi-armed activated T cells, laboratory biomarker analysis, therapeutic conventional surgery, Cytoxan®, Neosar® | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer | 06/15 | 11/15 | | |
NCT03406858: Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
|
|
| Completed | 2 | 15 | US | HER2Bi-Armed Activated T Cells, Anti-CD3 x Anti-Her2/neu Bispecific Antibody-Armed Activated T Cells, HER2Bi-Armed ATCs, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI) | Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7 | 01/21 | 11/22 | | |
